ClinicalTrials.gov
public full text
Public Domain
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
absenteeismanti-bacterial-agentsbacterial-infectionseconomicsmedicalpatient-satisfactionquality-of-life
The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin Structure Infections)
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)#136362
- A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris#1111687
- GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection#136375
- Pattern of Microbial Infection in AECOPD Patients and Its Sensitivity to Antibiotics#398335
- 1% Clascoterone Cream for the Treatment Acne Vulgaris#904957
Record · ID 901460
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive